{
  "id": "54f1e031c409818c32000001",
  "type": "factoid",
  "question": "DX-88 is investigational name of which drug?",
  "ideal_answer": "DX-88 is investigational name of a drug Ecallantide, a 60-amino acid recombinant protein discovered through phage display technology, that is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute hereditary angioedema attacks.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/18467921",
    "http://www.ncbi.nlm.nih.gov/pubmed/19093699",
    "http://www.ncbi.nlm.nih.gov/pubmed/18220151",
    "http://www.ncbi.nlm.nih.gov/pubmed/21481442",
    "http://www.ncbi.nlm.nih.gov/pubmed/14572819",
    "http://www.ncbi.nlm.nih.gov/pubmed/21760740",
    "http://www.ncbi.nlm.nih.gov/pubmed/16916274",
    "http://www.ncbi.nlm.nih.gov/pubmed/18613770"
  ],
  "snippets": [
    {
      "text": "Ecallantide (known as DX-88 previously), a potent and specific inhibitor of plasma kallikrein is an innovative medicinal product. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760740",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21481442",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Several novel therapies have completed phase III trials in the US, including: (i) plasma-derived C1-INH replacement therapies (Berinert P and Cinryze); (ii) a recombinant C1-INH replacement therapy (conestat alfa; Rhucin); (iii) a kallikrein inhibitor (ecallantide [DX-88]); and (iv) a bradykinin-2-receptor antagonist (icatibant).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19093699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18613770",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: Ecallantide (DX-88) is a potent and specific inhibitor of plasma kallikrein. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18613770",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "DX-88 (ecallantide), a 60-amino acid recombinant protein discovered through phage display technology, is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute HAE attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "DX-88 or ecallantide, a potent and specific inhibitor of plasma kallikrein, achieved all primary and secondary efficacy end points in a placebo-controlled, double-blind, phase 3 study, with a second phase 3 study ongoing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18220151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16916274",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16916274",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015507"
  ],
  "exact_answer": "Ecallantide"
}